Amgen (NASDAQ: AMGN), a leading biopharmaceutical company, has entered into a licensing agreement with CSL Vifor, securing the commercialization rights to Tavneos (avacopan) in Asia and Latin America, including mainland China. Avacopan is a first-in-class drug for the treatment of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis.
Originally approved in the US in October 2021, avacopan is indicated as adjuvant therapy for active severe ANCA associated vasculitis in adults, specifically microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA), and for use in combination with standard treatment regimens, including glucocorticoids. Its use with glucocorticoids cannot be eliminated by avacopan. Since its initial approval, the drug has received marketing authorizations in Canada, Australia, the UK, Germany, UAE, Japan, and South Korea.- Flcube.com
